Helsinn Group is reinforcing its cancer supportive care pipeline
Lugano, Switerland (ots) - The Company has entered the Phase III clinical program for both its investigational medications anamorelin, in non-small cell lung cancer-associated anorexia/cachexia, and netupitant + palonosetron oral fixed-dose combination in chemotherapy-induced nausea and vomiting (CINV) Helsinn, the Swiss pharmaceutical Group, global leader in the segment of the prevention of chemotherapy-induced nausea ...
plus